Back to search

Article

Characterization of the impact of daclizumab beta on circulating natural killer cells by mass cytometry

2019-12-05

Abstract excerpt

Daclizumab beta is a humanized monoclonal antibody that binds to CD25 and selectively inhibits high-affinity IL-2 receptor signaling. As a former treatment for relapsing forms of multiple sclerosis (RMS), daclizumab beta induces robust expansion of the CD56 bright subpopulation of NK cells that is correlated with the drug’s therapeutic effects. As NK cells represent a heterogeneous population of lymphocytes with...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
bd3a3c77-09f3-50b1-bc80-3f79bc5dbf62
DOI
10.1101/865477
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Characterization of the impact of daclizumab beta on circulating natural killer cells by mass cytometryDOI 10.1101/865477
Select a neighboring publication to make it the new centre.